QSC Tirzepatide represents a novel class of peptide therapeutics that combines the benefits of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonism. This innovative compound has shown significant potential in metabolic research applications.
As a research compound, QSC Tirzepatide demonstrates several pharmacological advantages:
1. Dual mechanism of action targeting both GLP-1 and GIP receptors
2. Glucose-dependent insulin secretion with minimal hypoglycemia risk
3. Potential weight reduction effects through appetite regulation
4. Possible pancreatic β-cell protection properties
Our QSC Tirzepatide is manufactured under strict quality control standards, ensuring high purity and consistency for research applications. The product undergoes comprehensive analytical testing including:
- High-performance liquid chromatography (HPLC) for purity verification
- Mass spectrometry (MS) for structural confirmation
- Amino acid analysis (AAA) when required
- Sterility testing for research-grade applications
Storage and handling recommendations:
- Store at -20°C for long-term preservation
- Protect from light and moisture
- Use within research laboratory settings only
Note: This product is intended for research use only, not for human consumption. Proper safety protocols should be followed when handling research peptides.